B-Cell Non-Hodgkin Lymphoma Drugs Market Size, Share and Growth Outlook, 2026

B-Cell Non-Hodgkin Lymphoma Drugs Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global B-Cell Non-Hodgkin Lymphoma Drugs Market size is forecast to increase from $3.79 Billion in 2026 to $5.73 Billion in 2034 at a CAGR of 5.3% between 2026 and 2034.

The B-Cell Non-Hodgkin Lymphoma Drugs market report provides detailed analysis and outlook of B-Cell Non-Hodgkin Lymphoma Drugs segments including By Drug Class (Monoclonal Antibodies, Kinase Inhibitors, CAR-T Cell Therapy, Antibody-Drug Conjugates, Chemotherapeutic Agents), By Disease Subtype (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Burkitt Lymphoma), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Oncology Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

B-Cell Non-Hodgkin Lymphoma (B-NHL) Drugs Industry Overview

Bispecific Antibodies Continue to Reshape B-NHL Treatment Strategies

The B-Cell Non-Hodgkin Lymphoma (B-NHL) Drugs industry is undergoing significant transformation as bispecific antibodies emerge as a major therapeutic class across multiple lymphoma subtypes. Pharmaceutical companies are increasingly focusing on immune-engaging therapies capable of targeting malignant B cells while activating the body's immune response. One of the most closely watched programs is epcoritamab (Epkinly®), developed by AbbVie and Genmab. The Phase 3 EPCORE® DLBCL-1 trial evaluated epcoritamab against conventional chemoimmunotherapy in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Although the study did not achieve its primary endpoint of overall survival, AbbVie reaffirmed its commitment to advancing epcoritamab through combination regimens and expanded development programs across hematologic malignancies. This continued investment highlights the industry's confidence in bispecific antibody platforms as an important component of future lymphoma treatment strategies, particularly for patients with relapsed or treatment-resistant disease.

Novel Combination Therapies Improve Outcomes in Relapsed and Refractory DLBCL

Treatment innovation within the B-NHL Drugs market is increasingly focused on improving survival outcomes for patients who are not candidates for intensive procedures such as autologous stem cell transplantation. A major advancement in this area is the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the approval of Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for adults with relapsed or refractory DLBCL who are ineligible for autologous stem cell transplant. Clinical findings from the Phase III STARGLO study demonstrated that the fixed-duration combination reduced the risk of death by 41% compared with the standard rituximab-GemOx regimen. These results reinforce the growing role of targeted immunotherapies in improving outcomes for heavily pretreated lymphoma patients and highlight the shift toward more effective, chemotherapy-enhanced biologic treatment approaches.

Subcutaneous Immunotherapy Expands Treatment Accessibility

The B-NHL therapeutics landscape is also benefiting from the growing adoption of convenient treatment modalities that improve patient experience and healthcare delivery efficiency. Following accelerated regulatory approval, Genmab and AbbVie have continued the global rollout of epcoritamab for relapsed or refractory follicular lymphoma. Clinical data presented during ongoing development programs demonstrated a high overall response rate among patients who had previously failed two or more lines of systemic therapy. As a subcutaneous bispecific antibody, epcoritamab offers practical administration advantages compared with more complex infusion-based therapies. The increasing availability of subcutaneous immunotherapies reflects a broader industry trend toward treatments that combine strong clinical efficacy with improved convenience, helping expand access to advanced lymphoma care while supporting evolving outpatient treatment models.

B-Cell Non-Hodgkin Lymphoma Drugs Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global B-Cell Non-Hodgkin Lymphoma Drugs market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Roche (Genentech), Bristol Myers Squibb, AbbVie, Johnson & Johnson (Janssen), Gilead Sciences (Kite Pharma), AstraZeneca, Novartis, Incyte Corporation, Beigene, Takeda Pharmaceutical. The B-Cell Non-Hodgkin Lymphoma Drugs market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the B-Cell Non-Hodgkin Lymphoma Drugs industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth B-Cell Non-Hodgkin Lymphoma Drugs Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by B-Cell Non-Hodgkin Lymphoma Drugs companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional B-Cell Non-Hodgkin Lymphoma Drugs markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

B-Cell Non-Hodgkin Lymphoma Drugs Market Competitive Benchmarking and Company Analysis

Leading companies in B-Cell Non-Hodgkin Lymphoma Drugs industry include- Roche (Genentech), Bristol Myers Squibb, AbbVie, Johnson & Johnson (Janssen), Gilead Sciences (Kite Pharma), AstraZeneca, Novartis, Incyte Corporation, Beigene, Takeda Pharmaceutical. The B-Cell Non-Hodgkin Lymphoma Drugs market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US B-Cell Non-Hodgkin Lymphoma Drugs Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the B-Cell Non-Hodgkin Lymphoma Drugs market remains one of the strongest-performing segments in the country.
The US B-Cell Non-Hodgkin Lymphoma Drugs Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US B-Cell Non-Hodgkin Lymphoma Drugs market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across B-Cell Non-Hodgkin Lymphoma Drugs industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian B-Cell Non-Hodgkin Lymphoma Drugs markets

Canada's strong B-Cell Non-Hodgkin Lymphoma Drugs sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian B-Cell Non-Hodgkin Lymphoma Drugs market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany B-Cell Non-Hodgkin Lymphoma Drugs Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest B-Cell Non-Hodgkin Lymphoma Drugs market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of B-Cell Non-Hodgkin Lymphoma Drugs population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany B-Cell Non-Hodgkin Lymphoma Drugs industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the B-Cell Non-Hodgkin Lymphoma Drugs market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support B-Cell Non-Hodgkin Lymphoma Drugs sales through 2034

France B-Cell Non-Hodgkin Lymphoma Drugs companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK B-Cell Non-Hodgkin Lymphoma Drugs Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of B-Cell Non-Hodgkin Lymphoma Drugs distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China B-Cell Non-Hodgkin Lymphoma Drugs Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China B-Cell Non-Hodgkin Lymphoma Drugs market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of B-Cell Non-Hodgkin Lymphoma Drugs industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese B-Cell Non-Hodgkin Lymphoma Drugs industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India B-Cell Non-Hodgkin Lymphoma Drugs Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian B-Cell Non-Hodgkin Lymphoma Drugs market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil B-Cell Non-Hodgkin Lymphoma Drugs market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa B-Cell Non-Hodgkin Lymphoma Drugs Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

B-Cell Non-Hodgkin Lymphoma Drugs Market Segmentation

By Drug Class
Monoclonal Antibodies
Kinase Inhibitors
CAR-T Cell Therapy
Antibody-Drug Conjugates
Chemotherapeutic Agents
By Disease Subtype
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Burkitt Lymphoma
By Route of Administration
Intravenous
Subcutaneous
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Specialty Oncology Pharmacies

Top Companies in B-Cell Non-Hodgkin Lymphoma Drugs Industry

Roche (Genentech)
Bristol Myers Squibb
AbbVie
Johnson & Johnson (Janssen)
Gilead Sciences (Kite Pharma)
AstraZeneca
Novartis
Incyte Corporation
Beigene
Takeda Pharmaceutical

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa